Welcome to the CReST2 Trial Website 

Important Message: COVID-19

We are now home-based during the COVID-19 pandemic but available and working. Responses may however take longer than normal as staff may be working altered hours but we are cross covering trials as required and urgent matters will be dealt with promptly. Please do not contact our usual office/landline number and instead email the trial contact and copy in the trial mailbox. If a query requires a prompt response please mark as ‘urgent’ in the email subject header.

CReST2 is a multicentre randomised controlled trial designed to provide reliable evidence on whether covered or uncovered stents are more effective in patients with obstructing colorectal cancer who are treated with palliative intent.

Trial Rationale

Colorectal cancer is the second most common cause of cancer death in the UK. Each year around 15% of people with colorectal cancer present with an obstruction. Patients are living longer with stents in situ, so choosing the right design of stent is important to maximise patients' quality of life. Two designs of stent are in common use in the UK today: covered and uncovered. Currently there is insufficient information to decide which of these two stent types is the best to use in people with colorectal cancer. CReST2 is designed to determine which stent design is the most efficacious in improving the quality of life in patients with bowel obstruction arising from colorectal cancer.

Trial Design

CReST2 is a 5 year, multi-centre randomised controlled trial. We aim to recruit 450 patients over five years. Patients will be randomised to received either a covered or uncovered endoluminal stent. 

Schema September 2017


The primary objectives of the CReST2 trial are to determine:

  1. If the Quality of Life for palliative colorectal cancer patients requiring a stent is dependent on whether the stent is covered or uncovered
  2. If the efficacy of the stent is dependent on whether the stent is covered or uncovered. 

The secondary objectives are to determine:

  1. If the technical success rates are different between covered and uncovered stents
  2. If the incidence of stent-related complications (perforation, blockage, migration) are different between covered and uncovered stents
  3. The rate of endoscopic re-interventions in each arm
  4. Whether the stent type used affects the stoma rate
  5. If the stent type used impacts on overall survival
  6. The cost effectiveness of implementing covered stents compared to uncovered stents

How to get involved...

CReST2 is open to recruitment and seeking new sites.

If your site would like to participate in the CReST2 trial, then please download the Site Registration Form and return it to the CReST2 Study Office:


CReST2 Study Office
Birmingham Clinical Trials Unit
Institute of Applied Health Research
Public Health Building
University of Birmingham
Birmingham B15 2TT

CReST2 is funded by the National Institute for Health Research’s HTA programme